Zevalin is a prescription drug approved by the Food and Drug Administration (FDA) to treat non-Hodgkin lymphoma (NHL). Specifically, Zevalin is indicated for use in low-grade or follicular B-cell lymphoma that has relapsed or failed to respond to treatment, or newly diagnosed follicular NHL that has responded to a first round of chemotherapy. Zevalin is prescribed in combination with Rituxan. Zevalin is also known by its drug name, Ibritumomab tiuxetan.
Zevalin is a type of immunotherapy. Zevalin is an antibody-isotope conjugate consisting of two parts. Ibritumomab is a biologic drug, a genetically engineered protein, or antibody, that targets the CD20 protein on lymphoma cells. Tiuxetan is a radioactive isotope. In combination, the antibody delivers radiation directly to lymphoma cells, where it causes cell death.read more
How do I take it?
Zevalin is administered as a one-time intravenous injection following two intravenous infusions of Rituxan.
Zevalin comes in the form of a single-dose vial.
The FDA-approved label for Zevalin lists common side effects including fever, fatigue, weakness, cough, cold or flu symptoms, nausea, diarrhea, and abdominal pain. Prolonged and severe low blood cell counts are a common and dangerous side effect experienced by most people who take Zevalin.
Rare but serious side effects listed for Zevalin can include life-threatening infusion reactions, the development of leukemia or myelodysplastic syndrome (a blood cell disorder), and potentially fatal skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If Zevalin leaks into the skin or tissue at the injection site (a situation known as extravasation), it causes a painful inflammatory reaction.
For more details about this treatment, visit:
Zevalin – Spectrum
Immunotherapy for Non-Hodgkin Lymphoma – American Cancer Society